Abstract：
OBJECTIVE: In the fall-winter of 2023, China experienced its first epidemic season of respiratory diseases since the COVID-19 pandemic. Gathering timely data about pathogenetic characteristics of respiratory infections is crucial to complement current respiratory surveillance mechanisms in China. Data from direct-to-consumer (DTC) multi-respiratory pathogen (MRP) testing could serve as a novel source of multi-pathogen data for community-based surveillance.
METHODS: A pioneering initiative was launched to detect multiple respiratory pathogens in Beijing and Guangzhou, China. DTC MRP tests were used to provide proactive surveillance ahead of medical services.
RESULTS: A total of 28,018 participants were enrolled between 22 August and 10 December 2023. Positive findings for at least one respiratory pathogen were observed in 26,202 (93.5%) participants. Influenza virus A, respiratory syncytial virus (RSV), and human adenovirus are the three leading viral pathogens detected with proportions of 18.0%, 10.6%, and 8.8%. Viral-bacterial pathogens were co-detected in 9736 (34.7%) of participants, which reduced to 22.2% for bacterial-bacterial co-detection, and 22.0% for bacterial mono-detection. The epidemiological ecology of respiratory pathogens within both viral clusters and specific pathogens varied among cities. The peak of RSV epidemics in Guangzhou occurred in the fall of 2023, earlier than in Beijing.
CONCLUSIONS: The innovative program offered enhanced surveillance capabilities beyond traditional methods, enabling prompt feedback about test results and mitigating the risk of cross-infection caused by waits in healthcare facilities.
METHODS: A pioneering initiative was launched to detect multiple respiratory pathogens in Beijing and Guangzhou, China. DTC MRP tests were used to provide proactive surveillance ahead of medical services.
RESULTS: A total of 28,018 participants were enrolled between 22 August and 10 December 2023. Positive findings for at least one respiratory pathogen were observed in 26,202 (93.5%) participants. Influenza virus A, respiratory syncytial virus (RSV), and human adenovirus are the three leading viral pathogens detected with proportions of 18.0%, 10.6%, and 8.8%. Viral-bacterial pathogens were co-detected in 9736 (34.7%) of participants, which reduced to 22.2% for bacterial-bacterial co-detection, and 22.0% for bacterial mono-detection. The epidemiological ecology of respiratory pathogens within both viral clusters and specific pathogens varied among cities. The peak of RSV epidemics in Guangzhou occurred in the fall of 2023, earlier than in Beijing.
CONCLUSIONS: The innovative program offered enhanced surveillance capabilities beyond traditional methods, enabling prompt feedback about test results and mitigating the risk of cross-infection caused by waits in healthcare facilities.
摘要：
目的：在2023年的秋冬季，中国经历了自COVID-19大流行以来的第一个呼吸道疾病流行季节。及时收集有关呼吸道感染的发病特征的数据对于补充中国当前的呼吸监测机制至关重要。来自直接对消费者（DTC）多呼吸道病原体（MRP）测试的数据可以作为基于社区的监测的多病原体数据的新来源。
方法：在北京和广州开展了一项检测多种呼吸道病原体的开创性举措，中国。直接面向消费者的多呼吸道病原体测试用于在医疗服务之前提供主动监测。
结果：2023年8月22日至12月10日，共有28,018名参与者入组。在26,202名（93.5％）参与者中观察到至少一种呼吸道病原体的阳性发现。流感病毒A(IFV-A),呼吸道合胞病毒(RSV)和人腺病毒(HAdV)是检测到的三种主要病毒病原体，比例为18.0％，10.6%和8.8%。在9,736（34.7％）的参与者中共同检测到病毒-细菌病原体，细菌-细菌共检测降至22.2%，细菌单一检测为22.0%。病毒簇和特定病原体中呼吸道病原体的流行病学生态学在城市之间有所不同。广州的RSV流行高峰出现在2023年秋季，早于北京。
结论：创新计划提供了超越传统方法的增强的监测能力，能够及时反馈测试结果，并降低因医疗机构等待而引起的交叉感染风险。
方法：在北京和广州开展了一项检测多种呼吸道病原体的开创性举措，中国。直接面向消费者的多呼吸道病原体测试用于在医疗服务之前提供主动监测。
结果：2023年8月22日至12月10日，共有28,018名参与者入组。在26,202名（93.5％）参与者中观察到至少一种呼吸道病原体的阳性发现。流感病毒A(IFV-A),呼吸道合胞病毒(RSV)和人腺病毒(HAdV)是检测到的三种主要病毒病原体，比例为18.0％，10.6%和8.8%。在9,736（34.7％）的参与者中共同检测到病毒-细菌病原体，细菌-细菌共检测降至22.2%，细菌单一检测为22.0%。病毒簇和特定病原体中呼吸道病原体的流行病学生态学在城市之间有所不同。广州的RSV流行高峰出现在2023年秋季，早于北京。
结论：创新计划提供了超越传统方法的增强的监测能力，能够及时反馈测试结果，并降低因医疗机构等待而引起的交叉感染风险。
